Form 4: Actuate Therapeutics CEO Daniel Schmitt Reports Stock Option Grants
SEC Form 4 Filing
Daniel Schmitt, CEO and Director of Actuate Therapeutics, reports the acquisition of employee stock options.
Summary
- Daniel Schmitt, the President, CEO, and Director of Actuate Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of two employee stock option grants on April 1, 2025.
- The first grant is for 66,503 shares with a strike price of $6.70, vesting 25% on April 1, 2026, and the remaining 75% vesting monthly over the following 36 months.
- The second grant is for 204,285 shares with a strike price of $6.70, vesting 25% on August 14, 2025, and the remaining 75% vesting monthly over the following 36 months.
- Both options expire on March 31, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their leadership teams.
- The vesting schedules and exercise prices are generally in line with industry norms for similar-sized companies.
Stakeholder Impact
- Shareholders may view the stock option grants as a positive incentive for the CEO.
- Employees may see the CEO's stock options as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of stock option grants |
| 08/14/2025 | First vesting date for the second option grant (25%) |
| 04/01/2026 | First vesting date for the first option grant (25%) |
| 03/31/2035 | Expiration date for both stock option grants |
Keywords
Form 4, Stock Options, Beneficial Ownership, Actuate Therapeutics, CEO, Daniel Schmitt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.